MiMedx reports Q1 adjusted EPS (5c), consensus (4c)

Reports Q1 revenue $58.99M, consensus $65.8M. Joseph H. Capper, MiMedx (MDXG) Chief Executive Officer, commented, “The first quarter of 2026 was adversely impacted as new Medicare reimbursement policies in the advanced wound care space went into effect at the start of the year and led to significant confusion across the industry in nearly every care setting. Additionally, inconsistent implementation by the Medicare Administrative Contractors created even greater challenges for providers and their patients.”